Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Stahel

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|March 7, 2006
Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesotheliomaD Lardinois, F J Jung, I Opitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13-17, 1996, Ermatingen, SwitzerlandP Bunn, D Carbone, J Grim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseB Besse, A Adjei, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2007
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancerG J Weiss, R Rosell, F Fossella, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2021
LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinomaM Gachechiladze, I Uberall, D Skanderova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2014
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-upJ Vansteenkiste, L Crinò, C Dooms, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2007
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03G D'Addario, D Rauch, R Stupp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2014
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)F Ciardiello, D Arnold, P G Casali, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trialC Gridelli, C Manegold, P Mali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2005
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)M Ghielmini, K Rufibach, G Salles, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
The Journal of Thoracic and Cardiovascular Surgery|March 7, 2006
Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesotheliomaD Lardinois, F J Jung, I Opitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13-17, 1996, Ermatingen, SwitzerlandP Bunn, D Carbone, J Grim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 27, 2014
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced diseaseB Besse, A Adjei, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2007
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancerG J Weiss, R Rosell, F Fossella, et al.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2021
LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinomaM Gachechiladze, I Uberall, D Skanderova, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2014
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-upJ Vansteenkiste, L Crinò, C Dooms, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2007
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03G D'Addario, D Rauch, R Stupp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2014
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)F Ciardiello, D Arnold, P G Casali, et al.
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trialC Gridelli, C Manegold, P Mali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 21, 2005
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)M Ghielmini, K Rufibach, G Salles, et al.
Pageof 8